Investors lap up shares of firms that may benefit from Monkeypox

As health authorities all over the globe search for ways to stop the monkeypox outbreak, investors are snapping up shares of companies that could benefit from the race to quell the disease.

Shares of vaccine producers, antiviral drug makers and protective equipment manufacturers are in demand as investors tap a strategy that delivered gains during the coronavirus pandemic. Biotechnological company Bavarian Nordic A/S and pharmaceutical firm Siga Technologies Inc. are among the stocks in focus as well as medical tools supplier Precision System Science Co.

While nowhere as severe as the Covid-19 outbreak, the spread of monkeypox infections across more than 70 countries in just a few months has prompted the World Health Organization to declare it as a global emergency. This pronouncement may give the trade an extra tailwind.

“At the moment, the world is relying on one manufacturer, Bavarian Nordic, for the monkeypox vaccine,” said Manish Bhargava, a fund manager at Straits Investment Holdings Pte in Singapore. “To keep up with demand, we can expect other biotech firms to ramp up research and production. It’s starting to reflect in the strong stock price performance for the sector.”

Here are some sectors and companies that have been active:

Vaccines and antivirals

Shares of Bavarian Nordic have more than tripled from a low in May after governments began ordering the Danish company’s monkeypox vaccine — the only one approved specifically to ward off the infection. The firm has raised its revenue guidance several times this year.

Analysts are taking note, with Citigroup Inc. increasing its target price for the company’s stock by 20 percent and flagging that there may be further upside if more orders come through. Shares of other companies making vaccines or antivirals for monkeypox have also caught the attention of US retail traders. The stock of Siga Technologies, which manufactures a treatment called Tpoxx, has doubled this year. The therapy is approved to treat smallpox in the US, and monkeypox and other viruses in the European Union and the UK.

Chimerix Inc.’s Tembexa is a countermeasure that is used to treat smallpox, and the firm said in May it would sell the drug to Emergent BioSolutions Inc. On the vaccine side, Emergent’s ACAM2000 is a smallpox vaccine that can be used in some cases against monkeypox. Siga, Chimerix and Emergent are the “key beneficiaries” of the WHO’s declaration that the monkeypox outbreak is a global emergency, according to Cowen Inc. analyst Boris Peaker. “With increased resources allocated to contact tracing and testing in the EU and US, we anticipate the case count to rise significantly over the next few months, potentially leading to more procurement of countermeasures,” Peaker wrote in a note.

Monkeypox declared a health emergency in NYC

Officials in New York City have declared a public health emergency due to the spread of the monkeypox virus, calling the city ‘the epicentre’ of the outbreak. The announcement Saturday by Mayor Eric Adams and Health Commissioner Ashwin Vasan said as many as 1,50,000 city residents could be at risk of infection.

The declaration will allow officials to issue emergency orders under the city health code and amend code provisions to implement measures to help slow the spread.

In the last two days, New York Gov. Kathy Hochul declared a state disaster emergency declaration and the state health department called monkeypox an “imminent threat to public health.” New York had recorded 1,345 cases as of Friday (Reuters).

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practice the journalism to which we are committed.

Support quality journalism and Subscribe to Business Standard.

Digital Editor